European Journal of Clinical and Experimental Medicine T.15, z. 2 (2017)
URI dla tej Kolekcji
Przeglądaj
Przeglądanie European Journal of Clinical and Experimental Medicine T.15, z. 2 (2017) według Autor "Tabarkiewicz, Jacek"
Aktualnie wyświetlane 1 - 4 z 4
Wyniki na stronie
Opcje sortowania
- Pozycja19F MRI As a tool for imaging drug delivery to tissue and individual cells(Wydawnictwo Uniwersytetu Rzeszowskiego, 2017) Bober, Zuzanna; Aebisher, David; Ożóg, Łukasz; Tabarkiewicz, Jacek; Tutka, Piotr; Bartusik-Aebisher, DorotaOver the past few decades, magnetic resonance imaging (MRI) has proven to be extremely successful in medical applications. More recently, the biomedical applications of MRI have been gaining more use in the field of clinical pharmacy. In 1977, perfluorocarbon compounds (PFC), which form emulsions that can carry drugs, were analyzed by 19F MRI and emulsified PFC compounds have been investigated as potential blood substitutes since the early 1960s and now a wide variety of PFC compounds are currently available as 19F MRI biomarkers. Molecules with 19F substituents are particularly attractive for use in drug tracking by 19F MRI due to 100% 19F abundance, high 19F MRI sensitivity (0.83 relative to 1H MRI) and an impressively large chemical shift range (400 ppm). Another benefit in the use of 19F MRI is a zero background signal in biological samples due to lack of endogenous fluorine. Therefore, drugs containing fluorine atom have potential for 19F MRI imaging drug delivery to tissue. This article will review recent developments in the use of 19F MRI in imaging drug delivery to tissue and individual cells.
- PozycjaAn overview of the preclinical and clinical studies of the effects of tumor treating fields on malignant glioma cells(Wydawnictwo Uniwersytetu Rzeszowskiego, 2017) Bądziul, Dorota; Banaś-Ząbczyk, Agnieszka; Tabarkiewicz, JacekAnaplastic astrocytoma (AA, WHO grade III) and glioblastoma multiforme (GBM, WHO grade IV) are malignant tumors of the brain. The average survival time of patients with GMB is approximately one year and two years in the case of anaplastic astrocytoma with standard therapy based on surgical tumor resection followed by chemotherapy or radiotherapy. High invasiveness of gliomas, the ability of rapid division and so-called diffusive infiltration of tumor cells into normal brain tissue, which prevents complete surgical removal, are hallmarks of theses tumors. Therefore, new specific therapies for eliminating cancer cells are needed to treat this tumors. Recently, it has been demonstrated that alternating electric field, also known as tumor treating fields (TTFields) has a unique mechanism of destroying glioma cells. TTFields applies electromagnetic energy frequency-dependent and intensitydependent and disrupts cancer cell replication as they undergo mitosis. Futhermore, TTFields turn out to act comparably to conventional chemotherapeutics, lacking numerous side adverse associated with chemotherapy. The authors provide an up-todate review of the mechanism of action as well as preclinical and clinical data on TTFields.
- PozycjaChemiluminescence-driven Dye Excitation for Dark Photodynamic Therapy(Wydawnictwo Uniwersytetu Rzeszowskiego, 2017) Ożóg, Łukasz; Tabarkiewicz, Jacek; Aebisher, DavidPhotodynamic therapy is a treatment that uses a combination of light-absorbing photosensitizers and dissolved oxygen to kill cancer. One specific limitation of photodynamic therapy is that the visible light used for photosensitizer excitation has a short tissue penetration depth of several millimeters. This limits the application of photodynamic therapy to surface cancers in the absence of a technique to illuminate deeper tissue. Efforts to extend tissue depth to which photodynamic therapy can be applied have been attempted with use of up-conversion and persistent-luminescent nanoparticles that absorb near infrared light and emit visible light for photosensitizer excitation, yet an initial excitation with an external light source is still required. More recently, systems employing chemiluminescence as an excitation energy source designed to bypass the use of external light have been developed and investigated as potential agents that could overcome the problem of achieving photodynamic therapy in deep tissue. We wish to provide an overview of several systems that have been recently reported that employ both radiative and non-radiative chemiluminescent energy transfer for photosensitizer excitation that have been developed in the hope of achieving “dark” photodynamic therapy. This article reviews several of these important new developments in the design of photodynamic therapeutic systems that utilize chemiluminescence.
- PozycjaInvestigation of pharmaceuticals by nuclear magnetic resonance imaging and spectroscopy(Wydawnictwo Uniwersytetu Rzeszowskiego, 2017) Bober, Zuzanna; Aebisher, David; Tabarkiewicz, Jacek; Guz, Wiesław; Tutka, Piotr; Bartusik-Aebisher, DorotaCurrently, new and easier ways of analyzing pharmaceutical drug forms and drug delivery mechanisms are being sought. Magnetic resonance imaging (MRI) is a non-invasive imaging technique that images drug forms such as tablets, liquids and topicals and drug form behavior in living organisms on both the tissue and cellular scale. The advantages of MRI include noninvasiveness, variable sample capacity and ease of transfer of phantom results to in vitro and in vivo studies. This review concerns the usefulness of clinical MRI that cannot be understated as this technique provides non-invasive and non-destructive insight into the properties of drug delivery systems. The research discussed here concerns the use of magnetic resonance, spectroscopy and chromatography to investigate selected pharmaceuticals and covers work of selecting drugs and antibodies for modification by synthesis for evaluation by MRI. Modifications have been aimed at improving therapeutic efficacy, delivery, and MRI. Modification conditions such as (pH, concentration, temperature, and the influence of other components present in the solutions) will be discussed to understand drug delivery system improvements and the reliability and repeatability of the results obtained. We hope to explore and expand the scope of pharmaceutical imaging with MRI for application in clinical medicine.